New Transcription Factors and Their Role in Diabetes and Therapy: Volume 5

ISBN-13: 9780444511584 / Angielski / Twarda / 2006 / 309 str.

Jacob E. Friedman

Opis

This book contains contributions from some of the most eminent experts in the fields of genetics, biochemistry, and pathophysiology of diabetes. Through specific examples, with broad applications, this book provides a comprehensive look at how transcription factors may underline the pathogenetic mechanisms of diabetes and obesity.

Volume 5 provides an overview of the status of the field, while also providing valuable information of practical utility to those who do not necessarily work in this field. The integration of basic biology with physiologically and clinically relevant proteins should provide the reader with a theoretical background to understanding the strategies for new potential therapeutic targets and their application to disease.

*Applies molecular biology to transcriptional regulation of metabolism and obesity
*Underscores the clinical relevance of transcription factors
*Provides a valuable overview of the current status of the field

Spis treści

1. PPARs as therapeutic targets for treating diabetes and insulin resistance
2. Genetic regulators of human obesity and diabetes
3. NF-kb, insulin resistance and the actions of salicylates
4. Wnt signaling and C/EBPs role in adipogenesis
5. Regulation of hepatic gluconeogenesis C/EPBs
6. Forkhead proteins and regulation of hepatic gene expression
7. Control of mitochondrial biogenesis through PGC-1
8. Regulation of PGC-1 in humans in insulin resistance and diabetes: Functional implications
9. FOXC2 controls resistance to obesity and Type II diabetes
10. SREB-1C regulation of nutrient homeostasis and lipid accumulation
11. GATA proteins as molecular gatekeeprs of the adipocyte
12. Diabetes regulation of gene expression by CREB
13. Molecular etiologies of MODY and other early-onset forms of diabetes
14. Liver X receptors as potential drug targets for Diabetes and its disorders
15. The potential therapeutic use of PPAR beta/delta agonists in lipid and glucose homeostasis
16. Influences of new PPAR insulin sensitizers on the metabolic syndrome in Rhesus Monkeys
17. PPARgamma and metabolism: Insights from the study of human genetic variants